Equitable Access to GLP-1 Receptor Agonists—Essential but Not Accessible
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
This Perspective discusses the actions needed to improve accessibility of glucagon-like peptide-1 (GLP-1) receptor agonists, especially in low- and middle-income countries, after their addition to the World Health Organization’s (WHO) Model List of Essential Medicines.
Appeared: Saturday, October 3. JAMA. Peer-reviewed journal.